Table 1 Demographic features and association between PLR and clinical features
Variables | Total (n = 238) | Q1 (n = 60) | Q2 (n = 60) | Q3 (n = 60) | Q4 (n = 58) | P value |
|---|---|---|---|---|---|---|
(38–349) | < 103 | > = 103–< 137 | >= 137–< 187 | > = 187 | ||
PLR | 152.64 ± 65.11 | 82.13 ± 16.03 | 121.51 ± 10.35 | 164.25 ± 14.34 | 245.78 ± 42.60 | < 0.001 |
Sex | ||||||
 Male | 179 (75.21%) | 42 (70.00%) | 45 (75.00%) | 51 (85.00%) | 41 (70.69%) | 0.204 |
 Female | 59 (24.79%) | 18 (30.00%) | 15 (25.00%) | 9 (15.00%) | 17 (29.31%) |  |
Age (years) | ||||||
Continuous | 60.26 ± 10.09 | 58.18 ± 9.77 | 59.17 ± 10.86 | 62.78 ± 9.55 | 60.95 ± 9.76 | 0.063 |
 <= 60 | 119 (50.00%) | 34 (56.67%) | 33 (55.00%) | 25 (41.67%) | 27 (46.55%) | 0.307 |
 > 60 | 119 (50.00%) | 26 (43.33%) | 27 (45.00%) | 35 (58.33%) | 31 (53.45%) |  |
BMI (kg/m2) | ||||||
Continuous | 24.05 ± 3.35 | 24.66 ± 3.40 | 24.54 ± 3.14 | 23.64 ± 2.97 | 23.33 ± 3.76 | 0.076 |
 < 25 | 139 (58.40%) | 31 (51.67%) | 29 (48.33%) | 39 (65.00%) | 40 (68.97%) | 0.061 |
 >= 25 | 99 (41.60%) | 29 (48.33%) | 31 (51.67%) | 21 (35.00%) | 18 (31.03%) |  |
Smoking status | ||||||
 No | 147 (61.77%) | 43 (71.67%) | 33 (55.00%) | 33 (55.00%) | 38 (65.52%) | 0.16 |
 Yes | 91 (38.23%) | 17 (28.33%) | 27 (45.00%) | 27 (45.00%) | 20 (34.48%) |  |
Operative approach | ||||||
 MIS | 83 (34.87%) | 28 (46.67%) | 27 (45.00%) | 13 (21.67%) | 15 (25.86%) | 0.004 |
 Open surgery | 155 (65.13%) | 32 (53.33%) | 33 (55.00%) | 47 (78.33%) | 43 (74.14%) |  |
Tumor size (cm) | ||||||
 Continuous | 4.24 ± 2.79 | 2.94 ± 1.91 | 3.90 ± 2.39 | 4.73 ± 2.95 | 5.45 ± 3.18 | < 0.001 |
 <= 4.0 | 112 (47.06%) | 44 (73.33%) | 28 (46.67%) | 26 (43.33%) | 14 (24.14%) | < 0.001 |
 > 4.0 | 126 (52.94%) | 16 (26.67%) | 32 (53.33%) | 34 (56.67%) | 44 (75.86%) |  |
CgA | ||||||
 Negative | 127 (53.36%) | 31 (51.67%) | 33 (55.00%) | 30 (50.00%) | 33 (56.90%) | 0.874 |
 Positive | 111 (46.64%) | 29 (48.33%) | 27 (45.00%) | 30 (50.00%) | 25 (43.10%) |  |
Syn | ||||||
 Negative | 28 (11.76%) | 8 (13.33%) | 5 (8.33%) | 9 (15.00%) | 6 (10.34%) | 0.673 |
 Positive | 210 (88.24%) | 52 (86.67%) | 55 (91.67%) | 51 (85.00%) | 52 (89.66%) |  |
Tumor type | ||||||
 NET | 51 (21.43%) | 18 (30.00%) | 18 (30.00%) | 7 (11.67%) | 8 (13.79%) | 0.015 |
 NEC | 137 (57.56%) | 27 (45.00%) | 31 (51.67%) | 37 (61.67%) | 42 (72.41%) |  |
 MiNEN | 50 (21.01%) | 15 (25.00%) | 11 (18.33%) | 16 (26.67%) | 8 (13.79%) |  |
Grade | ||||||
 G1–G2 | 62 (26.05%) | 23 (38.33%) | 17 (28.33%) | 12 (20.00%) | 10 (17.24%) | 0.04 |
 G3 | 176 (73.95%) | 37 (61.67%) | 43 (71.67%) | 48 (80.00%) | 48 (82.76%) |  |
T stage | Â | Â | Â | Â | Â | 0.17 |
 T1–T2 | 71 (29.83%) | 23 (38.33%) | 20 (33.33%) | 16 (26.67%) | 12 (20.69%) |  |
 T3–T4 | 167 (70.17%) | 37 (61.67%) | 40 (66.67%) | 44 (73.33%) | 46 (79.31%) |  |
N stage | ||||||
 N0 | 77 (32.35%) | 21 (35.00%) | 21 (35.00%) | 21 (35.00%) | 14 (24.14%) | 0.5 |
 N1–3 | 161 (67.65%) | 39 (65.00%) | 39 (65.00%) | 39 (65.00%) | 44 (75.86%) |  |
M stage | ||||||
 M0 | 193 (81.09%) | 53 (88.33%) | 49 (81.67%) | 49 (81.67%) | 42 (72.41%) | 0.177 |
 M1 | 45 (18.91%) | 7 (11.67%) | 11 (18.33%) | 11 (18.33%) | 16 (27.59%) |  |
Tumor stage | ||||||
 I–II | 93 (39.08%) | 27 (45.00%) | 26 (43.33%) | 23 (38.33%) | 17 (29.31%) | 0.298 |
 III–IV | 145 (60.92%) | 33 (55.00%) | 34 (56.67%) | 37 (61.67%) | 41 (70.69%) |  |
Chemotherapy | ||||||
 No | 182 (76.47%) | 42 (70.00%) | 44 (73.33%) | 53 (88.33%) | 43 (74.14%) | 0.086 |
 Yes | 56 (23.53%) | 18 (30.00%) | 16 (26.67%) | 7 (11.67%) | 15 (25.86%) |  |